Indian Union Health Minister Dr. Mansukh Mandaviya discussed India’s pharmaceutical industry and its global role with representatives of Japanese Pharma Companies in Tokyo.
Dr. Mandaviya highlighted India’s position as a reliable supplier of affordable and high-quality drugs, contributing significantly to global health outcomes. He emphasized India’s achievements in vaccine supply, generic exports, and provision of essential drugs during the COVID-19 pandemic. The minister mentioned the growth potential of the Indian pharmaceutical industry, with projections of reaching a value of US$ 130 billion by 2030. He also invited Japanese companies to explore investment and collaboration opportunities in India’s pharmaceutical market, including the areas of bio-pharmaceuticals, traditional medicines, and innovative therapies and technologies. Various officials from both countries attended the meeting.
Dr. Mandaviya urged Japanese companies to collaborate with India on research and innovation in advanced therapies such as precision medicine, cell and gene therapy, biological products, and digital tools. He emphasized that such partnerships would enhance the availability and affordability of innovative therapeutic options in India. The meeting was attended by officials from the Health Ministry, as well as executives from Japanese pharmaceutical companies such as Daiichi Sankyo Co., Ltd, Chugai Pharmaceutical Co., Ltd, Meiji Seika Pharma Co., Ltd, and Otsuka Chemical Co., Ltd.